Bone marrow and stem cell transplantation in Jordan has been performed since the 1990s, but the first comprehensive program was established at King Hussein Cancer Center (KHCC) in March 2003. The program, in addition to other health care institutions in Amman, serves approximately 5.6 million Jordanians. Also, we treat several patients per year from neighboring Arab countries. The program at KHCC performs an average of 80 transplants per year. During the past 4 years 320 patients received transplants at KHCC; 26% of them received an autologous graft and 74% allogeneic grafts. Of the allogeneic grafts 91% were taken from matched family members, 6.7% were haploidentical from one of the parents, and 2.3% were from an unrelated donor or umbilical cord blood. The actuarial overall survival among all patients has been around 65%. The most common indication for transplantation at KHCC was leukemia/ MDS followed by benign nonmalignant hematological/ immune deficiency/metabolic disorders, with thalassemia major being the most common among this group. The cost of SCT is variable and depends on many factors including the type of transplant and the attending post-transplant complications. The average charge for autologous transplant (both adults and pediatrics) is 24 695 JD (one JD equals 1.42 USD), and the average charge for allogeneic transplant (both adults and pediatrics) excluding haploidentical transplant is 46 787 JD. We have not noticed any peculiar patterns of complications following BMT; however, we have seen a high incidence of chronic GVHD following minitransplant with fludarabine and single-dose TBI (Seattle protocol). At the inception of the program, invasive fungal infection mainly related to building construction, and central line complications were significant. Measures implemented to control such complications were successful to a large extent. We report our results to the EBMT group and we are accredited as an unrelated transplantation center. Although from a young program, our group has presented abstracts to international conferences.
Introduction
Jordan has a population of about 5.6 million. Its health care services are primarily delivered by public (government) hospital and private profit and not-for-profit hospitals and clinics. Cancer care in Jordan is of special interest to the government because of its attendant high cost and severe psychosocial consequences. Cancer care is not covered by any Jordanian private health insurance firm. Therefore, all patients with cancer are fully covered financially in government hospitals, University Hospitals, the Royal Medical Services and King Hussein Cancer Center (KHCC). Most patients with cancer are treated at KHCC. In addition to Jordanians, many thousands of patients from neighboring countries seek medical care in Jordan because of quality and low cost compared to that in Europe and North America.
Bone Marrow and Stem Cell Transplantation has been performed in Jordan since early 1990s, but it was done at low annual rates at Jordan University Hospital, Royal Medical Services Hospital and in some private hospitals. Tables 1 and 2) .
A great majority of patients received traditional ablative conditioning prior to transplantation (78%) and 22% received either minimal conditioning or reduced intensity conditioning according to their underlying disease and their performance status at the time of transplantation (Table 3) . Although we started to transplant patients following reduced intensity conditioning at a relatively high rate in 2003 and 2004, this rate has decreased significantly because of the high rates of severe complications particularly chronic GVHD.
The indications for transplantation at KHCC have been similar to those of other BMT programs in the region with hematopoietic malignancies being by far the most common indication. On the other hand, and in contrast to programs from Europe and North America, 25% of transplants were done for immunodeficiency, metabolic and nonmalignant hematological disorders, many of them are either inherited or constitutional (Table 4) .
Survival
Of the 320 patients who were transplanted, 91 patients died (28%), and 229 patients are alive (72%). The actuarial survival for all patients is 65%. Actuarial survival for specific diseases will be presented at the conference. The survival for patients with thalassemia including those with class 2 and 3 disease, who were given a novel reduced intensity-conditioning regimen, is excellent.
Comments
The Bone Marrow and Stem Cell Transplantation Program at KHCC is a young program (4 years) but growing, and already the most difficult SCT procedures have been performed with acceptable results. It is a combined program for adult and pediatric patients with almost equal numbers being transplanted for each age group. The program is composed of 10 inpatient beds. There are five clinics per week and we serve our patients on a 24/7 basis.
Our stem cell laboratory procedures vary from simple cryopreservation for autologous patients, to highly purified cell population by positive or negative cell selection, using immunomagnetic separation.
Our stem cells laboratory was successfully able to collect cells from infants as low as 10 kg by apheresis.
Most of our patients are Jordanians who are insured by the Royal Court. Nevertheless, our group has ethical obligations toward the government in terms of patient selection and methods used, as BMT is a very expensive medical procedure. We also have patients referred from neighboring countries where funds are not usually readily available. Using only evidence-based protocols and supportive measures, we managed to reduce the cost of transplantation to a relatively acceptable level. Table 5 below shows the mean charges of each of the subtype of transplantations.
The most common indication for transplant at KHCC is leukemia/MDS. Among benign hematological disorders, thalassemia is the most common indication. On the waiting list we have around 90 patients with thalassemia who have a matched-related donor, awaiting transplant. The average waiting time is around 3 years to get to a transplantation unit. There is pressure from the community and the media to transplant thalassemia patients who do not have matched-related donors, using cord blood units. We are working to solve this problem by expanding the unit to 20 beds, and increase the number of the staff working in the program.
We are discussing the idea starting cord transplant for thalassemia patients, who do not have a matched-related donor, but one of the main prohibitive factors is the long waiting list for patients with matched siblings, the cost and the space required for such transplantation. We are in the process of establishing an Umbilical Cord Blood Bank at KHCC. From 2003 till the end of 2005 we noticed a relatively high incidence of post-transplant invasive aspergillus infection. During that period, a large amount of construction was made. The infectious diseases team implemented strict control on all construction at KHCC using portable HEPA filtration and other measures. During that period the utilization of antifungal agent (caspofungin and voriconazole) at KHCC skyrocketed. Soon after implementation of the strict protective measures, the incidence of invasive fungal infection had decreased to very low levels.
We also had an increased incidence of chronic GVHD in recipients of reduced intensity-and minimal intensityconditioning transplantation. This was particularly true for patients with CML. The unique organ involvement of chronic GVHD is worth noticing too because many of our patients had GVHD of the lungs.
